Form 4: Oncology Institute Director Acquires 52,000 Shares of Restricted Stock

Karen Marie Johnson, a director at Oncology Institute, acquired 52,000 shares of restricted stock on November 22, 2024.

Summary

• Karen Marie Johnson, a director at Oncology Institute, acquired 52,000 shares of restricted stock on November 22, 2024.
• The shares were acquired at a price of $0.
• These restricted stock units will vest in full on the date of TOI, Inc.'s 2025 annual shareholder meeting, contingent upon continued service with the company.
• Following this transaction, Ms. Johnson's total holdings in the company amount to 167,185 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a director increasing their stake in the company, which is generally a good sign. However, it's a standard transaction and not a major event.

Positives

• A director increasing their stake in the company can be seen as a positive sign of confidence in the company's future.

Risks

• The vesting of the restricted stock is contingent on continued service, which could be a risk if the director were to leave the company before the vesting date.

Future Outlook

The restricted stock units will vest in full on the date of TOI, Inc.'s 2025 annual shareholder meeting, subject to continued service with the company.

Industry Context

This is a standard transaction for a director receiving stock-based compensation, which is common in the biotech and healthcare industry.

Comparison to Industry Standards

• Stock grants to directors are a common practice in publicly traded companies, especially in the biotech sector, to align their interests with those of shareholders.
• The vesting schedule tied to continued service and the annual shareholder meeting is also a typical arrangement.
• Comparable companies often use similar stock-based compensation plans to attract and retain key personnel.

Stakeholder Impact

• Shareholders may view this as a positive sign of director confidence in the company.
• Employees may see this as a sign of stability and commitment from the leadership.

Next Steps

• The restricted stock units will vest on the date of the 2025 annual shareholder meeting, assuming continued service.

Key Dates

Keywords

Oncology Institute, Director, Restricted Stock, Share Acquisition, Form 4, Karen Marie Johnson, TOI